SCHEMBL19502864

SCHEMBL19502864

COc1ccc(CN2CC3C(C2)C3C(N)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.51
SIRT1 Q96EB6 1/20 0.51
SIGMAR1 Q99720 2/20 0.48
KDM4E B2RXH2 1/20 0.47
FAAH O00519 1/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9126843 0.80 S1PR5 (0.54) SIRT1SIGMAR1
SCHEMBL9126852 0.80 S1PR5 (0.54) SIRT1SIGMAR1
SCHEMBL19502865 0.80 SIGMAR1 (0.54) SIGMAR1KDM4ESMN1; SMN2DRD4
SCHEMBL15532870 0.78 S1PR5 (0.69) SIGMAR1KDM4E
SCHEMBL12488080 0.77 PAX8 (0.56) SIGMAR1KDM4ESMN1; SMN2DRD4
SCHEMBL12489466 0.77 PAX8 (0.56) SIGMAR1KDM4ESMN1; SMN2DRD4
SCHEMBL12488083 0.77 PAX8 (0.56) SIGMAR1KDM4ESMN1; SMN2DRD4
SCHEMBL12488076 0.77 PAX8 (0.56) SIGMAR1KDM4ESMN1; SMN2DRD4
SCHEMBL2918073 0.77 SIGMAR1 (0.57) SIGMAR1KDM4EFAAHPOLBSMN1; SMN2
SCHEMBL5196325 0.76 DRD4 (0.64) SIRT2SIRT1KDM4ESMN1; SMN2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464273-B9 IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS CHIESI FARM SPA (IT) 2020-10-21 EP claimed
EP-3464273-B1 IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS CHIESI FARM SPA (IT) 2020-04-08 EP claimed
US-20180009787-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-11 US claimed
US-9802919-B1 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2017-10-31 US claimed
EP-3464273-B9 IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS CHIESI FARM SPA (IT) 2020-10-21 EP disclosed
EP-3464273-B1 IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS CHIESI FARM SPA (IT) 2020-04-08 EP disclosed
US-10023558-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-07-17 US disclosed
US-20180009787-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-11 US disclosed
US-9802919-B1 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2017-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023558-B2 Compounds SERPINB1, ELANE, MPO SIRT2 1442/4885SIRT1 861/4885SIGMAR1 3139/4885
US-20180009787-A1 NOVEL COMPOUNDS SERPINB1, ELANE, MPO SIRT2 1337/4885SIRT1 882/4885SIGMAR1 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.